Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

Publication | Closed Access

DOI

165

Citations

References

2016

Year

Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, D Ward,

The Lancet HIV

Treatment And PreventionMedicineAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyPharmacotherapyHiv-1 InfectionFixed-dose CombinationsAntiviral DrugHivActive-controlled Phase 3PharmacologyAntiviral Compound